PMID- 15194601
OWN - NLM
STAT- MEDLINE
DCOM- 20040721
LR  - 20240322
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Print)
IS  - 0959-8138 (Linking)
VI  - 329
IP  - 7457
DP  - 2004 Jul 10
TI  - Atypical antipsychotic drugs in the treatment of behavioural and psychological 
      symptoms of dementia: systematic review.
PG  - 75
AB  - OBJECTIVE: To review the role of oral atypical antipsychotic drugs in the 
      management of the behavioural and psychological symptoms of dementia (BPSD). DATA 
      SOURCES: Medline, Embase, and the Cochrane Library. Reference lists were reviewed 
      and experts were contacted to identify additional trials. STUDY SELECTION: Double 
      blind randomised controlled trials that evaluated the four oral atypical 
      antipsychotic therapies for BPSD. REVIEW METHODS: Two reviewers assessed trial 
      validity independently. DATA EXTRACTION: Demographics of patients, study 
      duration, dose of antipsychotic, primary end points, adverse events. RESULTS: 77 
      abstracts were reviewed. Five randomised trials (1570 patients) evaluating 
      risperidone and olanzapine were identified. The quality of trials was generally 
      good. Most participants were in an institution (> 96%), elderly (weighted mean 
      82.3 years), and had Alzheimer's disease (76.3%). Trials lasted 6-12 weeks. 
      Treatment with atypical antipsychotic drugs was superior to placebo for the 
      primary end point in three of the five trials. Two trials comparing risperidone 
      with haloperidol did not find any differences in the primary measures of 
      efficacy. Adverse events were common and included extrapyramidal symptoms, 
      somnolence, and abnormal gait. CONCLUSIONS: Although atypical antipsychotic drugs 
      are being used with increasing frequency, few randomised trials have evaluated 
      their use for BPSD. Limited evidence supports the perception of improved efficacy 
      and adverse event profiles compared with typical antipsychotic drugs.
FAU - Lee, Philip E
AU  - Lee PE
AD  - Rotman Research Institute, Baycrest Centre for Geriatric Care, 3560 Bathurst 
      Street, Toronto, ON, Canada M6A 2E1. pelee@providencehealth.bc.ca
FAU - Gill, Sudeep S
AU  - Gill SS
FAU - Freedman, Morris
AU  - Freedman M
FAU - Bronskill, Susan E
AU  - Bronskill SE
FAU - Hillmer, Michael P
AU  - Hillmer MP
FAU - Rochon, Paula A
AU  - Rochon PA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20040611
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Antipsychotic Agents)
SB  - IM
CIN - BMJ. 2004 Aug 14;329(7462):404. PMID: 15310624
CIN - ACP J Club. 2005 Jan-Feb;142(1):15. PMID: 15656556
CIN - Evid Based Ment Health. 2005 Feb;8(1):16. PMID: 15671507
MH  - Administration, Oral
MH  - Antipsychotic Agents/*administration & dosage/adverse effects
MH  - Behavioral Symptoms/*drug therapy
MH  - Dementia/*drug therapy/psychology
MH  - Humans
MH  - Mental Disorders/drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC449807
EDAT- 2004/06/15 05:00
MHDA- 2004/07/22 05:00
PMCR- 2004/07/10
CRDT- 2004/06/15 05:00
PHST- 2004/06/15 05:00 [pubmed]
PHST- 2004/07/22 05:00 [medline]
PHST- 2004/06/15 05:00 [entrez]
PHST- 2004/07/10 00:00 [pmc-release]
AID - bmj.38125.465579.55 [pii]
AID - el-ppr75 [pii]
AID - 10.1136/bmj.38125.465579.55 [doi]
PST - ppublish
SO  - BMJ. 2004 Jul 10;329(7457):75. doi: 10.1136/bmj.38125.465579.55. Epub 2004 Jun 
      11.